85-1562-48　Lapatinib, Di-p-Toluenesulfonate Salt (N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Ditosylate, Lapatinib Ditosylate, Tykerb, GW-572016, Tyverb) 100mg　L1315-50

特徴

• Lapatinib inhibits both epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) tyrosine kinases by binding to the intracellular phosphorylation domain, preventing receptor autophosphorylation. The exact site of binding has currently not been confirmed. It appears to arrest the development of breast cancer in some patients with metastatic, treatment-refractory disease.
• Solubility:Soluble in DMSO at 200mg/ml; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10uM; buffers, serum, or other additives may increase or decrease the aqueous solubility.
• Elemental Anaylsis:Calculated:C=54.22%H=4.76%Cl=3.72%F= 1.99%N=5.88%S= 10.10%
• Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 6 months after receipt.

仕様

• Size：100mg
• Grade：Highly Purified
• Purity：~99%
• Form：Supplied as a yellow powder.
• Molecular Formula：C29H26ClFN4O4S•2C7H8O3S
• Molecular Weight Non Ab：925.46
• EU Commodity Code：38220090
• この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
• 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]